ClinicalTrials.gg

Program

CS2009

A development code.

Its studies are led by CStone Pharmaceuticals.

Furthest: phase 2, since Dec 15, 20241 company-led study, 1 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CStone Pharmaceuticals11 open or runningphase 2since Dec 15, 2024Dec 15, 2024Jan 2027phase 2 · NCT06741644

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2024First study: phase 2 study in Advanced Solid TumorsFirst studyNCT06741644 · 800 planned · United States, Australia, China

Ahead

  1. Jan 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT06741644

TargetBeta

CTLA4 →VEGFA →read by rule
“A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06741644Advanced Solid Tumors · United States, Australia, China2RecruitingJan 2027800

How it is read

Names in the registry

  • “CS2009”, 2 entries

Codes read as this program: CS2009.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.